Andrea L. Russo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea L. Russo has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Fisch
Massachusetts General Hospital 1 Department of Pathology Boston, Massachusetts
5 shared publications - Allison A. Gockley
Harvard Medical School, Boston, Massachusetts
5 shared publications - Annie R. Abruzzo
Harvard Medical School, Boston, Massachusetts
5 shared publications - Bayan A. Alzumaili
Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
5 shared publications - Daniel Lawrence Faden
Harvard Medical School, Boston, Massachusetts
5 shared publications - Dipon Das
Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA 02114, USA
5 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
Purpose:Human papillomavirus (HPV)–associated carcinomas (HPV+ cancers) account for 5% of all cancers. Circulating tumor HPV DNA (ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. Although HPV integration into the host genome is a proven tissue-based biomarker predicting poor clinical outcomes, existing clinically utilized ctHPVDNA assays cannot classify the viral physical state. Experimental Design:We previously developed HPV-DeepSeek, a multifeature HPV whole-genome sequencing liquid biopsy with 99% diagnostic accuracy at the time of HPV+ oropharyngeal cancer diagnosis. We tested the diagnostic accuracy of HPV-DeepSeek in a cohort of 235 HPV+ cancers across 9 anatomic sites and used a novel blood-based computational classifier to infer the HPV genome physical state from plasma, termed HPV sequencing-based integration analysis (HPV-SIGNAL), to assess its prognostic potential. Results:HPV-DeepSeek achieved 99% sensitivity and specificity. In 189 eligible samples, HPV-SIGNAL identified 4 viral physical states: episomal-only (n = 71), episomal-rearranged (n = 52), integrated-mixed (n = 57), and integrated-clonal (n = 9), which were confirmed and further elucidated via 3 orthogonal tissue and blood approaches. Patients harboring integrated viral states in blood exhibited significantly worse age-adjusted and American Joint Committee on Cancer stage–adjusted progression-free survival [PFS; HR, 2.78; 95% confidence interval (CI), 1.30–5.99; P = 0.009] and overall survival (OS; HR, 2.95; 95% CI, 1.01–8.61; P = 0.048) compared with patients with episomal states. Conclusions:HPV whole-genome sequencing liquid biopsy has high diagnostic accuracy across HPV+ cancer types and can be used to identify and classify HPV physical states from blood. Patients with integrated viral states detected in blood demonstrated worse PFS and OS, suggesting that blood-based HPV physical state classification could be used as a prognostic tool at the time of cancer diagnosis.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
Purpose:Human papillomavirus (HPV)–associated carcinomas (HPV+ cancers) account for 5% of all cancers. Circulating tumor HPV DNA (ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. Although HPV integration into the host genome is a proven tissue-based biomarker predicting poor clinical outcomes, existing clinically utilized ctHPVDNA assays cannot classify the viral physical state. Experimental Design:We previously developed HPV-DeepSeek, a multifeature HPV whole-genome sequencing liquid biopsy with 99% diagnostic accuracy at the time of HPV+ oropharyngeal cancer diagnosis. We tested the diagnostic accuracy of HPV-DeepSeek in a cohort of 235 HPV+ cancers across 9 anatomic sites and used a novel blood-based computational classifier to infer the HPV genome physical state from plasma, termed HPV sequencing-based integration analysis (HPV-SIGNAL), to assess its prognostic potential. Results:HPV-DeepSeek achieved 99% sensitivity and specificity. In 189 eligible samples, HPV-SIGNAL identified 4 viral physical states: episomal-only (n = 71), episomal-rearranged (n = 52), integrated-mixed (n = 57), and integrated-clonal (n = 9), which were confirmed and further elucidated via 3 orthogonal tissue and blood approaches. Patients harboring integrated viral states in blood exhibited significantly worse age-adjusted and American Joint Committee on Cancer stage–adjusted progression-free survival [PFS; HR, 2.78; 95% confidence interval (CI), 1.30–5.99; P = 0.009] and overall survival (OS; HR, 2.95; 95% CI, 1.01–8.61; P = 0.048) compared with patients with episomal states. Conclusions:HPV whole-genome sequencing liquid biopsy has high diagnostic accuracy across HPV+ cancer types and can be used to identify and classify HPV physical states from blood. Patients with integrated viral states detected in blood demonstrated worse PFS and OS, suggesting that blood-based HPV physical state classification could be used as a prognostic tool at the time of cancer diagnosis.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
Supplementary Figure S1. Exploration of HPV integration and rearrangement events using long-read sequencing
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
Supplementary Figure S1. Exploration of HPV integration and rearrangement events using long-read sequencing
- 17 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4936-4944
Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
Purpose: Human papillomavirus (HPV)–associated carcinomas (HPV+ cancers) account for 5% of all cancers. Circulating tumor HPV DNA (ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. Although HPV integration into the host genome is a proven tissue-based biomarker predicting poor clinical outcomes, existing clinically utilized ctHPVDNA assays cannot classify the viral physical state. Experimental Design: We previously developed HPV-DeepSeek, a multifeature HPV whole-genome sequencing liquid biopsy with 99% diagnostic accuracy at the time of HPV+ oropharyngeal cancer diagnosis. We tested the diagnostic accuracy of HPV-DeepSeek in a cohort of 235 HPV+ cancers across 9 anatomic sites and used a novel blood-based computational classifier to infer the HPV genome physical state from plasma, termed HPV sequencing-based integration analysis (HPV-SIGNAL), to assess its prognostic potential. Results: HPV-DeepSeek achieved 99% sensitivity and specificity. In 189 eligible samples, HPV-SIGNAL identified 4 viral physical states: episomal-only (n = 71), episomal-rearranged (n = 52), integrated-mixed (n = 57), and integrated-clonal (n = 9), which were confirmed and further elucidated via 3 orthogonal tissue and blood approaches. Patients harboring integrated viral states in blood exhibited significantly worse age-adjusted and American Joint Committee on Cancer stage–adjusted progression-free survival [PFS; HR, 2.78; 95% confidence interval (CI), 1.30–5.99; P = 0.009] and overall survival (OS; HR, 2.95; 95% CI, 1.01–8.61; P = 0.048) compared with patients with episomal states. Conclusions: HPV whole-genome sequencing liquid biopsy has high diagnostic accuracy across HPV+ cancer types and can be used to identify and classify HPV physical states from blood. Patients with integrated viral states detected in blood demonstrated worse PFS and OS, suggesting that blood-based HPV physical state classification could be used as a prognostic tool at the time of cancer diagnosis.
- 17 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4936-4944
Whole-Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification
Purpose: Human papillomavirus (HPV)–associated carcinomas (HPV+ cancers) account for 5% of all cancers. Circulating tumor HPV DNA (ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. Although HPV integration into the host genome is a proven tissue-based biomarker predicting poor clinical outcomes, existing clinically utilized ctHPVDNA assays cannot classify the viral physical state. Experimental Design: We previously developed HPV-DeepSeek, a multifeature HPV whole-genome sequencing liquid biopsy with 99% diagnostic accuracy at the time of HPV+ oropharyngeal cancer diagnosis. We tested the diagnostic accuracy of HPV-DeepSeek in a cohort of 235 HPV+ cancers across 9 anatomic sites and used a novel blood-based computational classifier to infer the HPV genome physical state from plasma, termed HPV sequencing-based integration analysis (HPV-SIGNAL), to assess its prognostic potential. Results: HPV-DeepSeek achieved 99% sensitivity and specificity. In 189 eligible samples, HPV-SIGNAL identified 4 viral physical states: episomal-only (n = 71), episomal-rearranged (n = 52), integrated-mixed (n = 57), and integrated-clonal (n = 9), which were confirmed and further elucidated via 3 orthogonal tissue and blood approaches. Patients harboring integrated viral states in blood exhibited significantly worse age-adjusted and American Joint Committee on Cancer stage–adjusted progression-free survival [PFS; HR, 2.78; 95% confidence interval (CI), 1.30–5.99; P = 0.009] and overall survival (OS; HR, 2.95; 95% CI, 1.01–8.61; P = 0.048) compared with patients with episomal states. Conclusions: HPV whole-genome sequencing liquid biopsy has high diagnostic accuracy across HPV+ cancer types and can be used to identify and classify HPV physical states from blood. Patients with integrated viral states detected in blood demonstrated worse PFS and OS, suggesting that blood-based HPV physical state classification could be used as a prognostic tool at the time of cancer diagnosis.
- 23 May 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 510-514
Understanding anxiety in patients receiving vaginal brachytherapy for low-grade early-stage endometrial cancer
- 23 May 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 510-514
Understanding anxiety in patients receiving vaginal brachytherapy for low-grade early-stage endometrial cancer
- 13 March 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 122 (5) , 1301-1309
Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix
- 13 March 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 122 (5) , 1301-1309
Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix